欢迎来到天天文库
浏览记录
ID:55681256
大小:378.84 KB
页数:5页
时间:2020-05-24
《解毒凉血方联合西药治疗乙型肝炎慢加急性肝衰竭患者64例临床观察.pdf》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、中医杂志2013年1i月第54卷第21期JournalofTraditionalChineseMedicine,2013,Vo1.54,No.21·1829·●临床研究解毒凉血方联合西药治疗乙型肝炎慢加急性肝衰竭患者64例临床观察刘慧敏王完波侯艺鑫高方媛孙凤霞江宇泳杨志云杜宏波王晓静周桂琴杨玉英王融冰(首部医科大学附属北京地坛医院中西医结合中心,北京市朝阳区京顺东街8号。100015)基金项目:国家“十一五”中医药防治传染病重大科技专项资助项目(2O08Zx10OO5—007);北京市科技计划资助项目(Z111107056811044);北京市中医药科技发
2、展基金资助项目(KJTS2011—05)*通讯作者:wangxianbo638@163.corn,(010)84322301[摘要]目的观察解毒凉血方联合西药治疗乙型肝炎慢加急性肝衰竭(ACLF)热毒瘀结证的临床疗效,并探讨其有效患者群。方法将105例热毒瘀结证乙型肝炎ACLF患者随机分为中西医结合组64例与西医治疗组41例。西医治疗组给予西医内科综合治疗,中西医结合组在西医治疗的基础上加用解毒凉血方,共治疗8周,随访4O周。比较两组治疗后第8、48周时的临床疗效,观察两组患者治疗第0、2、4、6、8、12、24、48周时中医证候积分及终末期肝病模型(ME
3、LD)评分,并根据MELD评分探讨有效患者群。结果治疗8周时,中西医结合组和西医治疗组总有效率分别为75.O0和51.22%,病死率分别为15.63和34.15,两组总有效率和病死率比较差异均有统计学意义(P4、间点MELD评分较治疗开始时下降(P<0.05);组间比较,中西医结合组治疗后第2~12周中医证候评分及第2、4、6、8周MELD评分均较同时间点西医治疗组降低(P<0.05)。MELD评分在22.6~29.9分的患者,中西医结合组的病死率为23.81,西医治疗组为58.82,两组比较差异有统计学意义(P5、n-ResolvingBlood-CoolingFormulaCombinedwithWesternMedicinefor64CasesofHepatitisBRelatedAcute-on-ChronicLiverFailureLIUHuimin,WANGXianbo,HOUYixin,GAOFangyuan,SUNFengxia,JIANGYuyong,YANGZhiyun,DUHongbo,WANGXiaojing,ZHOUGuiqin,YANGYuying,WANGRongbing(BeijingDitanHospital,CapitalMedic6、alUniversity,Beijing100015)ABSTRACTObjectiveToobservethetherapeuticeffectofToxin—ResolvingBlood—CoolingFormula(TRBCF)combinedwithwesternmedicineforhepatitisBrelatedacute—on-chronicliverfailure(HB-ACLF)withheat—toxinstasisbindpatternandresearchitseffectivepatientpopulation.MethodsT7、otally105HB-ACLFpatientswithheat—toxinstasisbindpatternwererandomizedintotheintegrativemedicinegroupof64casesandwesternmedicinegroupof41cases.Thewesternmedicinegroupwasgivenwesterncomprehensivetreatment.TheintegrativemedicinegroupwasaddedwithTRBCF.Thetreatmentlastedfor8weeksandthe8、follow—uplastedfor40weeks.Theclin
4、间点MELD评分较治疗开始时下降(P<0.05);组间比较,中西医结合组治疗后第2~12周中医证候评分及第2、4、6、8周MELD评分均较同时间点西医治疗组降低(P<0.05)。MELD评分在22.6~29.9分的患者,中西医结合组的病死率为23.81,西医治疗组为58.82,两组比较差异有统计学意义(P5、n-ResolvingBlood-CoolingFormulaCombinedwithWesternMedicinefor64CasesofHepatitisBRelatedAcute-on-ChronicLiverFailureLIUHuimin,WANGXianbo,HOUYixin,GAOFangyuan,SUNFengxia,JIANGYuyong,YANGZhiyun,DUHongbo,WANGXiaojing,ZHOUGuiqin,YANGYuying,WANGRongbing(BeijingDitanHospital,CapitalMedic6、alUniversity,Beijing100015)ABSTRACTObjectiveToobservethetherapeuticeffectofToxin—ResolvingBlood—CoolingFormula(TRBCF)combinedwithwesternmedicineforhepatitisBrelatedacute—on-chronicliverfailure(HB-ACLF)withheat—toxinstasisbindpatternandresearchitseffectivepatientpopulation.MethodsT7、otally105HB-ACLFpatientswithheat—toxinstasisbindpatternwererandomizedintotheintegrativemedicinegroupof64casesandwesternmedicinegroupof41cases.Thewesternmedicinegroupwasgivenwesterncomprehensivetreatment.TheintegrativemedicinegroupwasaddedwithTRBCF.Thetreatmentlastedfor8weeksandthe8、follow—uplastedfor40weeks.Theclin
5、n-ResolvingBlood-CoolingFormulaCombinedwithWesternMedicinefor64CasesofHepatitisBRelatedAcute-on-ChronicLiverFailureLIUHuimin,WANGXianbo,HOUYixin,GAOFangyuan,SUNFengxia,JIANGYuyong,YANGZhiyun,DUHongbo,WANGXiaojing,ZHOUGuiqin,YANGYuying,WANGRongbing(BeijingDitanHospital,CapitalMedic
6、alUniversity,Beijing100015)ABSTRACTObjectiveToobservethetherapeuticeffectofToxin—ResolvingBlood—CoolingFormula(TRBCF)combinedwithwesternmedicineforhepatitisBrelatedacute—on-chronicliverfailure(HB-ACLF)withheat—toxinstasisbindpatternandresearchitseffectivepatientpopulation.MethodsT
7、otally105HB-ACLFpatientswithheat—toxinstasisbindpatternwererandomizedintotheintegrativemedicinegroupof64casesandwesternmedicinegroupof41cases.Thewesternmedicinegroupwasgivenwesterncomprehensivetreatment.TheintegrativemedicinegroupwasaddedwithTRBCF.Thetreatmentlastedfor8weeksandthe
8、follow—uplastedfor40weeks.Theclin
此文档下载收益归作者所有